Aurobindo Pharma reported a 79.6% increase in Q4 net profit to ₹909 crore, with 17.1% revenue growth to ₹7,580 crore.
Aurobindo Pharma reported a 79.6% increase in its net profit to ₹909 crore for Q4 ended March 31, 2024. Revenue for the quarter increased by 17.1% to ₹7,580 crore from ₹6,473 crore in the corresponding period last year. For FY23-24, Aurobindo Pharma reported a net profit of ₹3,173 crore on a revenue of ₹29,002 crore. US formulations revenue grew by 21.6% YoY to ₹3,588 crore, with Europe formulations contributing ₹1,832 crore.
May 25, 2024
4 Articles